We are live on ! Find out more
NERV icon

Minerva Neurosciences

68 hedge funds and large institutions have $63.2M invested in Minerva Neurosciences in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more call options, than puts

Call options by funds: $964K | Put options by funds: $356K

1.22% less ownership

Funds ownership: 9.19%7.97% (-1.2%)

6% less funds holding

Funds holding: 7268 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

32% less capital invested

Capital invested by funds: $92.9M → $63.2M (-$29.7M)

35% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 26

Holders
68
Holders Change
-4
Holders Change %
-5.56%
% of All Funds
1.18%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
17
Reduced
26
Closed
19
Calls
$964K
Puts
$356K
Net Calls
+$608K
Net Calls Change
+$190K

NERV Hedge Fund Activity: Q2 2021 in Review

68 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q2 2021, worth a combined $63.2M — down 32% from $92.9M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of NERV and 15 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 17 added.

The largest buyer was Millennium Management, adding an estimated $1.94M. The largest seller was BlackRock, cutting an estimated $5.18M.

  • 68 institutional investors held Minerva Neurosciences (NERV) as of Q2 2021, down from 72 in Q1 2021.
  • Funds reported $63.2M of Minerva Neurosciences stock for Q2 2021, down 32% quarter-over-quarter.
  • 15 funds opened new Minerva Neurosciences positions in Q2 2021 and 19 closed out, a net change of -4 holders.
  • The largest Minerva Neurosciences buyer in Q2 2021 was Millennium Management, an estimated $1.94M added.
  • The largest Minerva Neurosciences seller in Q2 2021 was BlackRock, an estimated $5.18M sold.

Based on aggregated 13F filings for Q2 2021.